EPKINLY™ (Epcoritamab) delivers a 61% overall response rate in challenging-to-treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients 

EPKINLY™ is the seventh medicine developed by Genmab, utilizing their cutting-edge DuoBody® technology platform 

The U.S. FDA grants accelerated approval to EPKINLY™ as the first T-cell engaging bispecific antibody for adult patients with R/R DLBCL 

EPKINLY™ binds to both T-cells and CD20+ lymphoma B-cells, providing a dual-targeted approach to treat DLBCL effectively 

EPKINLY™ demonstrates a 38% complete response and a 15.6-month median duration of response in relapsed or refractory DLBCL patients 

The subcutaneous administration of EPKINLY™ offers an innovative treatment option for DLBCL patients in need of effective therapies